News

BofA downgrades Novavax stock on vaccine uncertainty

Bank of America cut its rating on Novavax (NASDAQ:NVAX) to Underperform from Neutral and lowered its price objective to $7 from $9, saying recent gains in the shares have overrun a still uncertain ...

Novavax downgraded to Underperform at BofA on growth uncertainties

Novavax (NVAX) downgraded to Underperform by BofA due to uncertain growth outlook despite cost-cutting measures. Read more ...
TipRanks on MSN7h

Novavax downgraded to Underperform at BofA on ‘murky outlook’

As previously reported, BofA downgraded Novavax (NVAX) to Underperform from Neutral with a price target of $7, down from $9, citing the recent ...